biostudies-literatureAhmed NNIEHS NIH HHSNCI NIH HHS5382-5396https://www.ebi.ac.uk/biostudies/studies/S-EPMC12597645biostudies-literatureUnknown9(20)<h4>Abstract</h4>Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. OBlood advancesReal-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.PMC1259764527398C0011U24 CA233032U24 CA07651827305C001127307C0011Locke FLAhmed SThiruvengadam SKDalton DLee DHerrera AFAhmed NWang MKharfan-Dabaja MAGerson JKloos IShadman MFrank MJBudde LETurtle CJGrover NBye MSauter CPasquini MCXu HHu ZHLogan BKim SHamadani MHematti PNunes AMoskop AfalseReal-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.<h4>Abstract</h4>Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. O2025-01-01T00:00:00Z2025 Oct2026-06-05T12:29:29.893Z2026-05-16T03:12:23.396ZS-EPMC125976454070603510.1182/bloodadvances.2024015014